Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.84 USD
Change Today +0.085 / 0.62%
Volume 261.2K
BDSI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 1:31 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biodelivery sciences intl (BDSI) Snapshot

Open
$13.74
Previous Close
$13.75
Day High
$14.11
Day Low
$13.65
52 Week High
09/12/14 - $18.48
52 Week Low
04/15/14 - $6.71
Market Cap
719.5M
Average Volume 10 Days
1.2M
EPS TTM
$-1.12
Shares Outstanding
52.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODELIVERY SCIENCES INTL (BDSI)

biodelivery sciences intl (BDSI) Related Businessweek News

No Related Businessweek News Found

biodelivery sciences intl (BDSI) Details

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer marketed under the BREAKYL name in Europe and PAINKYL name in Taiwan; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA for the treatment of chronic pain. The company also develops Clonidine Topical Gel, which is in Phase III clinical trial to treat painful diabetic neuropathy and other indications; and buprenorphine depot injection. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Arcion Therapeutics, Inc.; Evonik Corporation; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

29 Employees
Last Reported Date: 03/16/15
Founded in 1997

biodelivery sciences intl (BDSI) Top Compensated Officers

Chief Executive Officer, President, Chief Sci...
Total Annual Compensation: $751.4K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $370.9K
Executive Vice President of Product Developme...
Total Annual Compensation: $434.2K
Compensation as of Fiscal Year 2014.

biodelivery sciences intl (BDSI) Key Developments

BioDelivery Sciences International, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

BioDelivery Sciences International, Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company’s net revenue was $2.5 million compared to $4.0 million in the corresponding period of 2013. Net loss for the quarter was $17.6 million, or $0.51 per diluted share, compared to $12.8 million, or $0.33 per diluted share, in the corresponding period of 2013. For the year, the company’s net revenue was $38.9 million, compared to $11.4 million for full-year 2013. Loss from operations was $38.74 million against $56.402 million a year ago. Loss before taxes was $54.218 million against $57.394 million a year ago. Net loss was $54.2 million, or $1.12 per basic and diluted share, compared to $57.4 million, or $1.51 per basic and diluted share, for the year-ended December 31, 2013.

BioDelivery Sciences Seeks Acquisitions

BioDelivery Sciences International, Inc. (NasdaqCM:BDSI) said it will continue to position itself to execute upon the licensing and acquisition opportunities that will drive its next phase of growth.

BioDelivery Sciences International, Inc. to Report Q4, 2014 Results on Mar 16, 2015

BioDelivery Sciences International, Inc. announced that they will report Q4, 2014 results After-Market on Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDSI:US $13.84 USD +0.085

BDSI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Flamel Technologies SA $17.92 USD -0.035
Galena Biopharma Inc $1.38 USD 0.00
Skyepharma PLC 310.75 GBp -4.50
XenoPort Inc $7.13 USD +0.09
Zogenix Inc $1.33 USD +0.019
View Industry Companies
 

Industry Analysis

BDSI

Industry Average

Valuation BDSI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.4x
Price/Book 13.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODELIVERY SCIENCES INTL, please visit www.bdsi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.